UK medical cannabis: the access bottleneck, quantified

The UK medical cannabis market has an unusual shape: regulatory development has been slow, yet market development has been rapid. We estimate the patient base at around 91,000 in 2025, more than doubling to over 237,000 by 2029 — growth carried by private clinics, suppliers and pharmacies rather than by any loosening of the framework itself.

The sales trajectory follows. UK medical sales reach an estimated €265 million in 2025 and around €430 million by 2027 — the steepest climb of Europe's two largest medical markets, with the forecast to 2030 in the UK data pack. That makes the UK the continent's clearest case of demand outrunning regulation.

The bottleneck sits on the supply side. The market is open to new entrants but strictly regulated, with import licensing procedures a persistent obstacle. Most supply is imported — much of it classified as raw material, with final manufacturing completed domestically — although commercial domestic cultivation has risen quickly, and several UK operators now sell significant volumes of UK-grown flower, with more preparing to follow.

For operators, the read is straightforward: patient demand is not the constraint, throughput is. The advantage accrues to whoever solves licensing, supply relationships and clinic capacity first.